• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOMERIEUX SA THXID BRAF; THXID¿ BRAF

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOMERIEUX SA THXID BRAF; THXID¿ BRAF Back to Search Results
Catalog Number 410697
Device Problem Incorrect Or Inadequate Test Results (2456)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Type  malfunction  
Event Description
A customer in united states notified biomérieux of a product problem when using the thxid braf product.The customer reported after dilution of the positive control with 150 l as specified in the protocol, the nano drop quantity is around 2 ng/ l and the assay failed with an invalid positive control.The customer reported diluting the positive control with less volume (50 l), the nano drop reading is around 7 ng/ l.The assay did function correctly with a higher concentrated positive control.Due to the repeat testing before using another assay, the customer indicated a delay in reporting results.There is no indication or report from the customer that the product problem led to any adverse event related to the patient's state of health.An internal biomérieux investigation has been initiated.
 
Manufacturer Narrative
Biomérieux conducted an internal investigation: several tests were performed internally in order to check the performance of the product.A total of (b)(4) pc were tested and the results were within the expected specifications.Also, customer returned samples were analyzed and during the investigation it was noted that there was no fluorescence for both runs and for both targets (v600e and v600k) which is rare for the internal control.The discrepancy observed by the customer is likely due to handling or equipment used by the customer.It is recommended that the customer consult with the biomérieux local representative regarding handling steps described in the instruction for use, especially: - after addition of 150 ¿l of positive control diluent to the positive control sphere, mix at full speed using a vortex-type mixer until a clear solution has been obtained.- after addition of the 2 ¿l of positive control: several aspiration/dispensing with the pipette are necessary to allow a good homogenization of the pc in the mix.We advise to count a minimum of 5 aspiration/dispensing.Since the root cause of the discrepancy is related to use error no corrective action is warranted at this time.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
THXID BRAF
Type of Device
THXID¿ BRAF
Manufacturer (Section D)
BIOMERIEUX SA
chemin de l orme
marcy l etoile, rhone 69280
FR  69280
Manufacturer (Section G)
BIOMERIEUX, INC
595 anglum road
st. louis MO 63042
Manufacturer Contact
ellen weltmer
595 anglum road
st. louis, MO 63042
MDR Report Key6211049
MDR Text Key63621005
Report Number3002769706-2016-00533
Device Sequence Number1
Product Code OWD
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P120014
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional,user faci
Reporter Occupation Health Professional
Type of Report Initial,Followup
Report Date 02/21/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue Number410697
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 12/06/2016
Initial Date FDA Received12/28/2016
Supplement Dates Manufacturer ReceivedNot provided
Supplement Dates FDA Received02/21/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Type of Device Usage N
Patient Sequence Number1
-
-